NCT05470868View on ClinicalTrials.gov

Safety and Tolerability of PRO-185

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 4, 2023

Primary Completion Date

May 22, 2023

Study Completion Date

May 22, 2023

Conditions
Hyperemia Eye
Interventions
DRUG

Naphazoline / Hypromellose Ophthalmic

Naphazoline 0.03% / Hypromellose 0.2%

Trial Locations (1)

44650

IIMET Investigación e Innovación en Medicina Translacional, Guadalajara

All Listed Sponsors
lead

Laboratorios Sophia S.A de C.V.

INDUSTRY